Vertigo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major vertigo markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2024-2034.
The vertigo market has been comprehensively analyzed in IMARC’s new report titled “Vertigo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Vertigo refers to chronic or cyclical sensations of balance loss in which a person feels as though their surroundings are moving when they are not. There are two forms of vertigo, i.e., peripheral and central. The most common type is peripheral vertigo, which is caused by a problem in the vestibular nerve or the inner ear that connects the inner ear and the brain. Central vertigo occurs when the brain, notably the cerebellum, malfunctions. Dizziness is the most prevalent symptom of vertigo, which is exacerbated by further head motions. Other symptoms of this indication include an increased amount of sweating, hypertension, nausea and vomiting, a screeching or humming sensation in the ears, hearing impairment, reflexive eye movements, and balance difficulties. Vertigo symptoms might range in duration from a few minutes to many hours or even longer. Usually, a doctor starts the diagnosis by performing multiple tests to determine the condition of the vestibular system. These include electronystagmography, rotation tests, a head thrust test, a caloric reflex test, and computerized dynamic posturography. Post that, physical examinations are performed on the patient to determine whether it is central or peripheral vertigo. CT scans, MRIs, auditory brainstem response tests, pure tone and speech audiometry testing, and electrocochleography are also included in the diagnostic procedure for vertigo.
The increasing number of individuals suffering from ear-related illnesses, such as benign paroxysmal positional vertigo (BPPV) and Meniere’s disease, which enhances the prevalence of vertigo, is primarily driving the global market. In addition to this, the rising incidences of sports-related head injuries and the growing alcohol consumption are also creating a positive outlook for the market. Moreover, the prolonged use of several medications, including anti-seizure pills, blood thinners, antidepressants, pain relievers, etc., is further bolstering the market growth. Besides this, the emerging popularity of vestibular test battery, which includes various tests to help identify the problems of the inner ear, is also propelling the global market. Additionally, the increasing utilization of canalith repositioning maneuvers, a series of specific head and body movements that are carried out to treat benign paroxysmal positional vertigo (BPPV) through the induced out-migration of free-moving pathological densities in the endolymph of a semicircular canal, is further positively influencing the market growth. Apart from this, several government bodies are introducing initiatives to raise awareness regarding vertigo and its treatment, which has led to the incorporation of tracking vertigo conditions in routine check-ups. This, in turn, is also acting as a significant growth-inducing factor. Moreover, the widespread adoption of vestibular rehabilitation training (VRT) for people suffering from recurrent vertigo bouts is expected to drive the vertigo market during the forecasted period.
IMARC Group’s new report provides an exhaustive analysis of the vertigo market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vertigo and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vertigo market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the vertigo market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the vertigo market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current vertigo marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the vertigo market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the vertigo market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the vertigo market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the vertigo patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of vertigo ?
What will be the growth rate of patients across the seven major markets?
Vertigo: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for vertigo drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vertigo market?
The vertigo market has been comprehensively analyzed in IMARC’s new report titled “Vertigo Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Vertigo refers to chronic or cyclical sensations of balance loss in which a person feels as though their surroundings are moving when they are not. There are two forms of vertigo, i.e., peripheral and central. The most common type is peripheral vertigo, which is caused by a problem in the vestibular nerve or the inner ear that connects the inner ear and the brain. Central vertigo occurs when the brain, notably the cerebellum, malfunctions. Dizziness is the most prevalent symptom of vertigo, which is exacerbated by further head motions. Other symptoms of this indication include an increased amount of sweating, hypertension, nausea and vomiting, a screeching or humming sensation in the ears, hearing impairment, reflexive eye movements, and balance difficulties. Vertigo symptoms might range in duration from a few minutes to many hours or even longer. Usually, a doctor starts the diagnosis by performing multiple tests to determine the condition of the vestibular system. These include electronystagmography, rotation tests, a head thrust test, a caloric reflex test, and computerized dynamic posturography. Post that, physical examinations are performed on the patient to determine whether it is central or peripheral vertigo. CT scans, MRIs, auditory brainstem response tests, pure tone and speech audiometry testing, and electrocochleography are also included in the diagnostic procedure for vertigo.
The increasing number of individuals suffering from ear-related illnesses, such as benign paroxysmal positional vertigo (BPPV) and Meniere’s disease, which enhances the prevalence of vertigo, is primarily driving the global market. In addition to this, the rising incidences of sports-related head injuries and the growing alcohol consumption are also creating a positive outlook for the market. Moreover, the prolonged use of several medications, including anti-seizure pills, blood thinners, antidepressants, pain relievers, etc., is further bolstering the market growth. Besides this, the emerging popularity of vestibular test battery, which includes various tests to help identify the problems of the inner ear, is also propelling the global market. Additionally, the increasing utilization of canalith repositioning maneuvers, a series of specific head and body movements that are carried out to treat benign paroxysmal positional vertigo (BPPV) through the induced out-migration of free-moving pathological densities in the endolymph of a semicircular canal, is further positively influencing the market growth. Apart from this, several government bodies are introducing initiatives to raise awareness regarding vertigo and its treatment, which has led to the incorporation of tracking vertigo conditions in routine check-ups. This, in turn, is also acting as a significant growth-inducing factor. Moreover, the widespread adoption of vestibular rehabilitation training (VRT) for people suffering from recurrent vertigo bouts is expected to drive the vertigo market during the forecasted period.
IMARC Group’s new report provides an exhaustive analysis of the vertigo market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for vertigo and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the vertigo market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the vertigo market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the vertigo market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current vertigo marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the vertigo market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the vertigo market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the vertigo market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the vertigo patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of vertigo ?
What will be the growth rate of patients across the seven major markets?
Vertigo: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for vertigo drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the vertigo market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VERTIGO - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 VERTIGO - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VERTIGO - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 VERTIGO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VERTIGO - UNMET NEEDS
10 VERTIGO - KEY ENDPOINTS OF TREATMENT
11 VERTIGO - MARKETED PRODUCTS
11.1 List of Vertigo Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VERTIGO - PIPELINE DRUGS
12.1 List of Vertigo Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VERTIGO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 VERTIGO - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Vertigo - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Vertigo - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Vertigo - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Vertigo - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Vertigo - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Vertigo - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Vertigo - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Vertigo - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Vertigo - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Vertigo - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Vertigo - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Vertigo - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Vertigo - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Vertigo - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Vertigo - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Vertigo - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Vertigo - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Vertigo - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Vertigo - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Vertigo - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Vertigo - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Vertigo - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Vertigo - Access and Reimbursement Overview
15 VERTIGO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 VERTIGO MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VERTIGO - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 VERTIGO - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VERTIGO - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 VERTIGO - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VERTIGO - UNMET NEEDS
10 VERTIGO - KEY ENDPOINTS OF TREATMENT
11 VERTIGO - MARKETED PRODUCTS
11.1 List of Vertigo Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 VERTIGO - PIPELINE DRUGS
12.1 List of Vertigo Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VERTIGO - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 VERTIGO - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Vertigo - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Vertigo - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Vertigo - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Vertigo - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Vertigo - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Vertigo - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Vertigo - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Vertigo - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Vertigo - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Vertigo - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Vertigo - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Vertigo - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Vertigo - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Vertigo - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Vertigo - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Vertigo - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Vertigo - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Vertigo - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Vertigo - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Vertigo - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Vertigo - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Vertigo - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Vertigo - Access and Reimbursement Overview
15 VERTIGO - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 VERTIGO MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
